Merck’s first quarter of 2026 shows revenue growth to $16.3 billion but a net loss of $4.24 billion largely due to significant acquisition-related charges. The company’s recent acquisitions of Terns Pharmaceuticals and Cidara Therapeutics enhance its clinical pipeline, particularly in oncology and antiviral sectors. Strategic collaborations with AstraZeneca and Eisai continue to underpin revenue streams. Going forward, Merck’s growth will hinge on successful integration of new assets, regulatory approvals, and sustained innovation in core therapeutic areas.